Drug Detail

Information about OSI-930

Generic Name
IND	OSI-930
Brand Name (US)
Manufacturer	OSI
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 1
Indications
Overall Strategy	KIT Protein Based
Strategy	Block KIT
Drug Category	KIT inhibitor VEGFR inhibitor (TKI)

Mechanism of Action
OSI-930 is a multi-targeted tyrosine kinase inhibitor that is designed to act as a potent co-inhibitor of the receptor tyrosine kinases c-Kit and VEGFR-2. The inhibition of the tyrosine kinase activity of Kit is expected to result in reduced cancer cell proliferation and increased cellular apoptosis in tumor types driven by Kit, resulting in inhibition of tumor growth. OSI-930 is also capable of inhibiting VEGFR-2. This receptor is present on endothelial cells and is a key mediator of blood vessel growth in response to the angiogenic growth factor VEGF. This pathway is believed to be the single most important mechanism for recruitment of new blood vessels in nearly all solid tumors. Inhibition of this pathway should therefore impact the growth and metastases of a wide range of angiogenesis-dependent malignancies.